An FDA review panel approved drugs, saying they met safety standards for treating bipolar and schizophrenia in children. AstraZeneca's Seroquel and Pfizer Inc.'s Geodone were approved; Eli Lilly's Zyprexa was given back-up status should the others fail. All have been the subject of controversial court cases involving allegations of withholding information and dangerous side effects. An FDA report indicates children already account for something between 5 percent and 11 percent of these drugs, bringing the total to five for the number of "antipsychotic" drugs available for kids. Careful post-marketing surveillance will be essential, David Shern, CEO of Mental Health America, told the Wall St. Journal Health Blog.
Consider This
by Phyllis Vine
MIWatch.org on Facebook
Relevant Sites
- Visit the Illinois neurology department of Northshore
Featured Videos
Most Popular
MIWatch Archives
This site complies with the HONcode standard for trustworthy health information:
verify here.
